Flagship International Flexible Fund IC Limited (An Incorporated Cell of IPFM Guernsey ICC Limited)

Annual Report and Audited Financial Statements For the year ended 31 October 2022

Contents	Page	
General Information	2	
Company Structure	3	
Cell Manager's Report	4	
Directors' Report	5 - 6	
Custodian Report	7	
Supplementary Information	8	
Portfolio Statement	9	
Independent Auditor's Report	10 - 12	
Statement of Financial Position	13	
Statement of Comprehensive Income	14	
Statement of Cash Flows	15	
Statement of Changes in Net Assets attributable to Participating Shareholders	16	
Notes to the Financial Statements	17 - 27	

#### **General Information**

#### **Registered Office**

Ground Floor Dorey Court Admiral Park St Peter Port, Guernsey Channel Islands

GY1 2HT

## Directors of the Company and the Cell

Brett Patton
James Tracey (resigned 29 April 2022)
Simon Sharrott
Graham Sleep (from 8 April 2022)

## **Investment Manager and Promoter**

IP Fund Managers Guernsey Limited Ground Floor Dorey Court Admiral Park St Peter Port, Guernsey Channel Islands GY1 2HT

#### Cell Manager and Distributor

Flagship Asset Management (Pty) Limited 1st Floor ICR House Alphen Office Park Constantia Main Road Constantia, Cape Town 7800 South Africa

## **Legal Advisors**

Carey Olsen (Guernsey) LLP P.O. Box 98 Carey House Les Banques St Peter Port, Guernsey Channel Islands GY1 4BZ

#### Custodian

Butterfield Bank (Guernsey) Limited P.O. Box 25 Regency Court Glategny Esplanade St Peter Port, Guernsey Channel Islands GY1 3AP

# Administrator, Registrar, Secretary and Paying Agent

JTC Fund Solutions (Guernsey) Limited Ground Floor Dorey Court Admiral Park St Peter Port, Guernsey Channel Islands GY1 2HT

#### **Independent Auditor**

BDO Limited Place Du Pre Rue Du Pre St Peter Port, Guernsey Channel Islands GY1 3LL

## **Company Structure**

Flagship International Flexible Fund IC Limited (the "Cell") is an open ended investment scheme incorporated in Guernsey on 21 December 2007 in accordance with The Companies (Guernsey) Law, 2008, (the "Law") and The Authorised Collective Investment Schemes (Class B) Rules and Guidance, 2021 (the "Class B Rules") as issued by the Guernsey Financial Services Commission pursuant to the Protection of Investors (Bailiwick of Guernsey) Law, 2020 (the "POI Law"). The Cell is an incorporated cell of IPFM Guernsey ICC Limited (the "Company").

The Law allows an Incorporated Cell Company ("ICC") to create one or more incorporated cells for the purpose of segregating and protecting the assets within those cells so that liabilities attributable to one cell can only be satisfied out of the assets of that cell, and creditors and shareholders of a particular cell have no right to the assets of any other cell or the ICC. Each incorporated cell is a single legal person separate from the ICC of the incorporated cell company and any other incorporated cells.

A cell is not a subsidiary of its ICC. Whilst an ICC can own shares in its own cells and one cell may own shares in another cell of the same ICC (unless prohibited by the cell's memorandum and articles of incorporation), a cell cannot own shares in its ICC. Each cell will have their own constitutional arrangements and membership of an incorporated cell is distinct from that of another cell. Members of one incorporated cell are not, by virtue of that fact, members either of the ICC or any other incorporated cell. Thus, for voting purposes, a member of an incorporated cell of an ICC may not, in that capacity, vote at a general meeting of the ICC or vice versa.

Each incorporated cell must have a board of directors. To the extent that the board of directors of a cell comprises the same persons as the board of directors of the ICC itself, the directors must meet separately in their capacity as directors of each incorporated cell and, in that capacity, they owe their fiduciary and other duties to the relevant incorporated cell rather than to the ICC. Conversely, when they meet as directors of the ICC they owe their duties to the ICC rather than to any of its incorporated cells.

Each incorporated cell is responsible for the preparation of its accounts in accordance with the Law. The rights and obligations of the holders of participating shares are governed by the Articles of Incorporation of the relevant cell. Copies of the Articles of Incorporation of a cell may be altered by the passing of a special resolution of the cell.

The Cell was formed on 21 December 2007. Audited financial statements have been produced for the year ended 31 October 2022. The Cell was transferred into the Company on 1 July 2020. Subsequent to this, the year end for the Cell was changed from 30 June to 31 October to align with the Company's year end. Therefore, the comparative period is from 1 July 2020 to 31 October 2021.

## **Cell Manager's Report**

For the year ended 31st of October 2022, Flagship International Flexible Fund IC Limited returned minus 29.66% in US dollars versus the fund's benchmark, the MSCI ACWI, which returned minus 14.42%.

2022 saw the equity market give up many of the gains it made in 2021. The reasons for this were many. Inflation which had already begun to rise towards the end of 2021, continued its upward trend to levels last seen in the 1970's. Central banks had no choice but to respond by raising interest rates which lead to an increase in the discount rate the market uses to discount future earnings from equities. The sharp increase in interest rates also led to a sharp sell-off in bonds which fell 16.4% during the year.

While good asset allocation offset some of the poor performance from stock selection in the prior year, both factors worked against the fund in 2022. The funds average allocation to equities, which was the asset class which performed the worst, was 68% versus 50% for our benchmark. The fact that the fund had no exposure to bonds helped but was not able to compensate for our "over-weight" equities position.

With respect to the detractors, the largest single detractor was the fund's investment in Flagship Global Icon Fund IC Limited, an equity fund, (-8.96%) as it represented 20% of the fund's holdings.

Russia's invasion of Ukraine contributed directly to the equity sell-off, firstly by contributing to a surge in inflation (as a result of higher commodity prices) and secondly, because it resulted in a heightened perception of geopolitical risk globally. It also had a direct negative impact on some of the fund's holdings.

Zalando, a German online fashion retailer, and TCS, a Russian bank, fell 4.22% on a combined basis. In Zalando's case the market was worried about the impact surging gas prices would have on Germany's economy, while the fund's holding in TCS had to be written down completely due to sanctions the West imposed on Russia. Good performances from the oil stocks in the fund, up 60 bps on a combined basis, helped but not sufficiently.

Other notable performances were from Hyprop which was the second largest contributor (+0.3%) and Pagseguro (-1.78%), a Brazilian merchant acquirer, which was the second largest detractor.

2023 is proving to be another interesting year for markets. Interest rates have continued their ascent and the interest rate hiking cycle that commenced in 2022 is proving to be one of the steepest ever. This has not been without unintended negative consequences, as the failure of Silicon Valley Bank and Credit Suisse demonstrate. We believe broad equity valuations do not reflect the prevailing market risks and are seeking to buttress our portfolio by reducing equity exposure and tilting our stock selection towards more defensive sectors.

Flagship Asset Management (Pty) Limited Cell Manager Date: 25 April 2023

## **Directors' Report**

The Directors present their annual report together with audited financial statements of Flagship International Flexible Fund IC Limited (the "Cell") for the year ended 31 October 2022.

The Cell was transferred into the Company on 1 July 2020. Subsequent to this, the year end for the Cell was changed from 30 June to 31 October to align with the Company's year end. Therefore, the comparative period is from 1 July 2020 to 31 October 2021.

#### **Principal Activities**

The Cell, with registration number 48255, is a Guernsey registered Incorporated Cell of IPFM Guernsey ICC Limited (the "Company"). Refer to page 3 on company structure.

The Cell aims to provide long term capital growth and in order to attempt to achieve this has invested in a portfolio biased toward equities, but also into a wide range of other asset classes including cash, fixed income, commodities and property and exposure will be taken in a wide range of currencies and markets. The Cell is ideally suited to investors with an above average risk tolerance and with an investment horizon of five years or longer.

The Cell intends to achieve its investment objective by actively-managed portfolio that is spread across a broad range of asset classes and currencies in varying proportions over time. These asset classes include equity, bond, property, as well as money market instruments. The Cell may invest in securities that directly represent the relevant asset class, or it may invest in underlying portfolios of Collective Investment Schemes or other similar schemes that provide exposure to the relevant asset classes, or invest in a combination of the two. Out-performance is targeted through aggressive asset allocation, and focused security and underlying portfolio selection, based on in-house proprietary models of the Cell Manager and extensive internal and external research.

The Cell's investment activities are managed by IP Fund Managers Guernsey Limited (the "Manager") and Flagship Asset Management (Pty) Limited acts as the Cell Manager.

#### **Directors**

The Directors of the Cell during the year and at the date of this Report are set out on page 2.

#### **Directors' interests**

None of the Directors who held office during the year and at the date of this Report had any disclosable interests in the shares of the Cell.

#### Directors' responsibilities

The Directors are responsible for preparing the financial statements for each financial year, which give a true and fair view, in accordance with applicable Guernsey law and International Financial Reporting Standards, of the state of affairs of the Cell and of the profit or loss of the Cell for that period. In preparing these financial statements, the Directors are required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- Prepare the financial statements on the going concern basis, unless it is inappropriate to presume that the Cell will continue in business.

The Cell Manager has delegated responsibility for compliance with the Class B Rules to the Directors and the Directors confirm that they have complied with the above requirements in preparing the financial statements.

## **Directors' Report (continued)**

## Directors' responsibilities (continued)

The Directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Cell and enable them to ensure that the financial statements comply with The Companies (Guernsey) Law, 2008 and the Protection of Investors (Bailiwick of Guernsey) Law, 2020 and the Class B Rules. They are also responsible for safeguarding the assets of the Cell and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

#### Disclosure of information to auditor

So far as each Director is aware, there is no relevant audit information of which the Cell's auditor is unaware and each Director has taken all the steps they ought to have as a Director to make themselves aware of any relevant audit information and to establish that the Cell's auditor is aware of that information.

## Financial statements publication

The audited financial statements of the Cell are published on the Cell Manager's website. The Cell Manager is responsible for the maintenance and integrity of the website; the work carried out by the auditor does not involve consideration of these matters and, accordingly, the auditor accepts no responsibility for any changes that may occur to the financial statements after they are initially presented on the website, The Directors appreciate there is uncertainty regarding legal requirements of information published on the internet as it is accessible in many countries and legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

#### Going concern

The financial statements have been prepared on a going concern basis. The Directors believe that this basis is appropriate as the Cell consists predominantly of securities that are readily realisable, has significant net assets, minimal creditors, is not dependent on any external finance or support from other group entities and as at the date of these financial statements has sufficient cash and bank balances to meet its expected run rate expenses for at least twelve months from the date of signing.

The Russian invasion of Ukraine, alongside the imposition of international sanctions continue to have a pervasive economic impact, not only on businesses within Russia and Ukraine, but also globally where businesses engage in economic activities that might be affected by the recent developments. The war is increasingly affecting economic and global financial markets and exacerbating ongoing economic challenges, including issues such as rising inflation and global supply-chain disruption. The war has had a direct negative impact on some of the fund's holdings. As a result of this, the Directors continue to actively monitor the situation on a regular basis.

#### Independent auditor

BDO Limited are the auditor of the Cell and have expressed their willingness to continue in office.

On behalf of the Board

#### **GRAHAM SLEEP**

Director

Date: 26 April 2023

## Custodian's Report to the Members of Flagship International Flexible Fund IC Limited

In our opinion, the Cell has, in all material aspects, been managed for the year ended 31 October 2022 in accordance with the provisions of the Principal Documents, Scheme Particulars and The Authorised Collective Investment Schemes (Class B) Rules and Guidance, 2021.

## **ANDREW THOMPSON**

For and on behalf of Butterfield Bank (Guernsey) Limited

Date: 26 April 2023

# **Supplementary Information**

		31.10.2022	31.10.2021
1.	Number of shares outstanding Class A shares	23,092,092	23,168,134
2.	<b>Net asset value per share</b> Class A shares	0.95	1.46
3.	Highest/ Lowest prices Class A shares Class B shares	1.49/0.92 -/-	1.59/1.13 1.59/-
4.	<b>Number of shares subscribed</b> Class A shares	173,846	357,319
5.	Number of shares redeemed Class A shares Class B shares	249,888	4,214,327 357,062

# **Portfolio Statement**

Financial Assets at fair value through profit or loss	Holdings	Fair value USD	% of Net assets
Equities: 40.49% (2021: 61.68%)			
Basic Materials iShares MSCI Global Gold Miners ETF Sedibelo Platinum Mines	15,265 2,000,000	281,792 208,643	1.28 0.95
Finance	2,000,000 _	490,435	2.23
iShares Global Financials ETF TCS Group Holding PLC	5,910 4,100	395,261 12,710	1.79 0.06
General	4,100 _	407,971	1.85
iShares Global Materials ETF	4,649	333,147	1.51
iShares MSCI ACWI ETF iShares MSCI ACWI UCITS ETF	26,035 31,100	1,858,847	9.77 8.44
Vanguard FTSE All-World UCITS ETF	21,740 _	2,091,388 6,436,997	9.50 29.22
<b>Healthcare</b> iShares Trust Global Healthcare ETF	6,509	533,087	2.42
Property	_	533,087	2.42
Nuveen Short-term REIT ETF	34,370 _	1,052,066 1,052,066	4.77
	_	· ,	4.77
Total Equities	_	8,920,556	40.49
Collective Investment Schemes: 26.05% (2021: 25.11%)			
<b>Commodity Funds</b> Flagship Global Icon Fund	538,550	4,127,716	18.73
Satrix SA Bond ETF	2,161,955	931,391	4.23
SPDR Gold Shares	4,482 _	680,950	3.09
		5,740,057	26.05
<b>Total Collective Investment Schemes</b>	_	5,740,057	26.05
Total financial assets at fair value through profit or loss	_	14,660,613	66.54
<b>.</b>	_	·	
Other net assets: 33.46% (2021: USD 4,500,881; 13.32%)		7,372,977	33.46
Net assets attributable to holder of participating redeemable shares	_ _	22,033,590	100.00

# Independent Auditor's Report to the Members of Flagship International Flexible Fund IC Limited

#### Opinion on the financial statements

In our opinion, the financial statements of Flagship International Flexible Fund IC Limited ("the Cell"), an incorporated cell of IPFM Guernsey ICC Limited:

- give a true and fair view of the state of the Cell's affairs as at 31 October 2022 and of its loss for the year then ended;
- have been properly prepared in accordance with IFRS; and
- have been properly prepared in accordance with the requirements of the Companies (Guernsey) Law, 2008.

We have audited the financial statements of the Cell for the year ended 31 October 2022 which comprise the Statement of Financial Position, the Statement of Comprehensive Income, the Statement of Cash Flows, the Statement of Changes in Net Assets Attributable to Participating Shareholders and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS").

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Cell in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the Directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Cell's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Directors with respect to going concern are described in the relevant sections of this report.

#### Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material misstatement in the financial statements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

# Independent Auditor's Report to the Members of Flagship International Flexible Fund IC Limited (continued)

#### Other Companies (Guernsey) Law, 2008 reporting

We have nothing to report in respect of the following matters where the Companies (Guernsey) Law, 2008 requires us to report to you if, in our opinion:

- proper accounting records have not been kept by the Cell; or
- the financial statements are not in agreement with the accounting records; or
- we have failed to obtain all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

#### **Responsibilities of Directors**

As explained more fully in the Directors' responsibilities within the Directors' Report, the Directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Directors are responsible for assessing the Cell's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Cell or to cease operations, or have no realistic alternative but to do so.

#### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Extent to which the audit was capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Based on our understanding of the Cell and the sector in which it operates, we identified that the principal risks of non-compliance with laws and regulations related to its investment activities and we considered the extent to which non-compliance might have a material effect on the Cell's financial statements.

We obtained an understanding of the legal and regulatory frameworks that are applicable to the Cell and have a direct impact on the preparation of the financial statements. We determined that the most significant framework which is directly relevant to specific assertions in the financial statements is the financial reporting framework, IFRS. We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of management override of controls) and determined that the principal risks were related to revenue recognition, net asset value based fees and management bias in accounting estimates, specifically to those in relation to the valuation of the investments.

We communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

# Independent Auditor's Report to the Members of Flagship International Flexible Fund IC Limited (continued)

Audit procedures performed by the engagement team to respond to the risks identified included:

- Discussion with and enquiry of management and those charged with governance concerning known or suspected instances of non-compliance with laws and regulations or fraud;
- Reading minutes of meetings of those charged with governance, correspondence with the Guernsey Financial Services Commission, internal compliance reports, complaint registers and breach registers to identify and consider any known or suspected instances of non-compliance with laws and regulations or fraud;
- Obtaining an understanding of the internal control environment in place to prevent and detect irregularities;
- Recalculating the net asset value based fees based on the relevant scheme particulars, comparing the recalculated amounts with that of management and challenging management on any resulting differences;
- Recalculating investment income and realised and unrealised gains and losses on investments in full based on external source information; and
- Testing the valuation of all listed investments held by agreeing the prices used in the valuation to independent third-party sources.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities is available at the Financial Reporting Council's website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

#### Use of our report

This report is made solely to the Cell's members, as a body, in accordance with Section 262 of the Companies (Guernsey) Law, 2008. Our audit work has been undertaken so that we might state to the Cell's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Cell and the Cell's members as a body, for our audit work, for this report, or for the opinions we have formed.

#### **BDO Limited**

Chartered Accountants Place du Pré Rue du Pré St Peter Port Guernsey

Date: 27 April 2023

## **Statement of Financial Position**

Assets	Notes	31.10.2022 USD	31.10.2021 USD
Current Assets Financial assets at fair value through profit or loss Cash and cash equivalents Dividends receivable Other receivables	2.5; 6	14,660,613 7,439,168 - 380 <b>22,100,161</b>	29,352,596 4,591,215 1,043 996 33,945,850
Total assets	=	22,100,161	33,945,850
Liabilities Current Liabilities Financial liabilities at fair value through profit or loss Other payables Capital shares redeemed payable Liabilities (excluding net assets attributable to	_	66,019 549	66,690 92,370 -
participating shareholders) Net assets attributable to participating shareholders Total liabilities	8 _	66,568 22,033,590 <b>22,100,158</b>	159,060 33,786,787 33,945,847
Equity Management shares Total equity	7 _	3 3	3 3
Total equity and liabilities	_	22,100,161	33,945,850
Net asset value per participating shareholders Class A – USD	8	0.95	1.46

The notes on pages 17 to 27 form part of these financial statements.

These financial statements were approved and authorised for issue by the Board of Directors on 26 April 2023 and signed on its behalf by:

## **GRAHAM SLEEP**

Director

## **Statement of Comprehensive Income**

		Year ended	Period from 01.07.2020
	Notes	31.10.2022 USD	to 31.10.2021 USD
Income Net (loss)/gain on financial assets held at fair value through	6	(11.046.000)	10.020.004
profit or loss	6	(11,046,888)	10,028,094
Dividend income		180,292	255,187
Interest income		21,627	-
Net other foreign exchange losses	_	(310,736)	(1,150,816)
Total net (loss)/income		(11,155,705)	9,132,465
Expenses			
Audit fee		(8,635)	(8,434)
Custodian fee	3	(13,310)	(17,436)
Investment management fee	3;9	(79,862)	(515,974)
Management and administration fee	3;9	(399,325)	(103,409)
Directors fee	3;9	(1,476)	(1,433)
Sundry expense	_	(36,854)	(101,239)
Total operating expense		(539,462)	(747,925)
Net (loss)/profit before tax		(11,695,167)	8,384,540
Withholding tax	<u>-</u>	(26,985)	(33,062)
(Loss)/profit for the year/period and total comprehensive income attributable to participating shareholders	<del>-</del>	(11,722,152)	8,351,478

All items in the above statement derive from continuing operations. There is no difference between the increase in net assets attributable to participating shareholders and comprehensive income.

The notes on pages 17 to 27 form part of these financial statements.

## **Statement of Cash Flows**

	Year ended	Period from 01.07.2020
	31.10.2022 USD	to 31.10.2021 USD
Cash flow from operating activities		
(Loss)/profit for the year/period	(11,722,152)	8,351,478
Adjustments for:		
Net losses/(gains) on financial assets at fair value through profit or loss	11,046,888	(10,028,094)
Net settlement on other foreign exchange losses	310,736	1,150,816
Dividend income	(180,292)	(255,187)
Withholding tax	26,985	33,062
Operating loss before working capital changes	(517,835)	(747,925)
Net decrease/(increase) in other receivables	616	(586)
Net (decrease)/increase in other payables	(26,351)	26,533
Purchase of financial assets at fair value through profit or loss	(19,721,370)	(29,614,646)
Sale of financial assets at fair value through profit or loss	23,299,775	36,441,068
Dividend received	154,350	223,596
Net cash generated from operating activities	3,189,185	6,328,040
Cash flow from financing activities		
Cash received from issuance of participating shares	223,963	523,258
Cash paid on redemptions of participating shares	(254,459)	(5,593,760)
Net cash used in financing activities	(30,496)	(5,070,502)
National and and and archaete	2.450.600	4 255 520
Net increase in cash and cash equivalents	3,158,689	1,257,538
Cash and cash equivalents at the beginning of the year/period	4,591,215	4,484,493
Net settlement on other foreign exchange gains	(310,736)	(1,150,816)
Cash and cash equivalents at the end of the year/period	7,439,168	4,591,215

The notes on pages 17 to 27 form part of these financial statements.

# Statement of Changes in Net Assets attributable to Holders of Participating Redeemable Shares

	Year ended 31.10.2022 USD	Period from 01.07.2020 to 31.10.2021 USD
Net assets attributable to participating shareholders at the beginning of the year/period	33,786,787	30,505,811
Proceeds from issuance of participating shares Payments on redemption of participating redeemable shares Total comprehensive income attributable to participating shareholders	223,963 (255,008) (11,722,152)	523,258 (5,593,760) 8,351,478
Net assets attributable to participating shareholders at the end of the year/period	22,033,590	33,786,787

The notes on pages 17 to 27 form part of these financial statements.

#### **Notes to Financial Statements**

#### 1. General information

Flagship International Flexible IC Limited (the "Incorporated Cell" or the "Cell"), with company number 48255, was a Guernsey registered, Limited Liability Incorporated Cell of Momentum Mutual Fund ICC Limited (the "Company"). From 13 July 2020, the Cell was a Limited Liability Incorporated Cell of IPFM Guernsey ICC Limited.

The Cell aims to provide long term capital growth and in order to attempt to achieve this has invested in a portfolio biased toward equities, but also into a wide range of other asset classes including cash, fixed income, commodities and property and exposure will be taken in a wide range of currencies and markets. The Cell is ideally suited to investors with an above average risk tolerance and with an investment horizon of five years or longer.

The Cell intends to achieve its investment objective by actively-managed portfolio that is spread across a broad range of asset classes and currencies in varying proportions over time. These asset classes include equity, bond, property, as well as money market instruments. The Cell may invest in securities that directly represent the relevant asset class, or it may invest in underlying portfolios of Collective Investment Schemes or other similar schemes that provide exposure to the relevant asset classes, or invest in a combination of the two. Out-performance is targeted through aggressive asset allocation, and focused security and underlying portfolio selection, based on in-house proprietary models of the Cell Manager and extensive internal and external research.

Up to 30 June 2020, the Cell's investment activities were managed by Momentum Wealth International Limited (the "Manager"), with the investment management delegated to Momentum Global Investment Management Limited (the "Investment Manager"). From 13 July 2020, the Cell's investment activities are managed by IP Fund Managers Guernsey Limited and Flagship Asset Management (Pty) Limited acts as the Cell Manager.

#### 2. Summary of significant accounting policies

The principal accounting policies detailed below have been consistently applied in the preparation of the financial statements of the Cell.

#### 2.1 Basis of preparation

The financial statements of the Cell have been prepared on a going concern basis, in accordance with International Financial Reporting Standards (IFRS).

The financial statements have been prepared at an incorporated Cell ("IC") level. The non-cellular assets and liabilities are in respect of the management shares issued by the Company, as disclosed in note 7.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires the Directors of the Company to exercise judgement in the process of applying the Cell's accounting policies.

#### 2.2 Going concern

The financial statements have been prepared on a going concern basis. The Directors believe that this basis is appropriate as the Cell consists predominantly of securities that are readily realisable, has significant net assets, minimal creditors, is not dependent on any external finance or support from other group entities and as at the date of these financial statements has sufficient cash and bank balances to meet its expected run rate expenses for at least twelve months from the date of signing.

The Russian invasion of Ukraine, alongside the imposition of international sanctions continue to have a pervasive economic impact, not only on businesses within Russia and Ukraine, but also globally where businesses engage in economic activities that might be affected by the recent developments. The war is increasingly affecting economic and global financial markets and exacerbating ongoing economic challenges, including issues such as rising inflation and global supply-chain disruption. The war has had a direct negative impact on some of the fund's holdings. As a result of this, the Directors continue to actively monitor the situation on a regular basis.

## **Notes to Financial Statements (continued)**

### 2. Summary of significant accounting policies (continued)

## 2.3 New and revised standards, interpretations and amendments

The accounting policies used in the preparation of the financial statements have been consistently applied during the year ended 31 October 2022.

There were no new standards, amendments or interpretations applicable for the year that had a material impact on the financial statements.

There are no standards, amendments or interpretations in issue at the reporting date which have been issued but are not yet effective and that are deemed to be material to the Company.

#### 2.4 Foreign currency translation

The functional and presentation currency of the Cell is United States Dollar ("USD"). Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income. Translation differences on non-monetary financial assets and liabilities such as equities at fair value through profit or loss are recognised in the Statement of Comprehensive Income within the fair value net gain or loss.

#### 2.5 Financial instruments

#### (a) Financial assets

The Cell's financial assets are classified as those to be measured at fair value through profit or loss and those to be measured at amortised cost. The classification depends on the Cell's business model for managing the financial assets and the contractual terms of the cash flows. Financial assets are measured initially at fair value adjusted by directly attributable transaction costs, except for those carried at fair value through profit or loss with transaction costs recognised directly in profit or loss.

#### Financial Assets held at amortised cost

Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. These assets are subsequently measured at amortised cost using the effective interest method. The effective interest method calculates the amortised cost of financial instruments and allocates the interest over the period of the instrument.

The Cell's financial assets held at amortised cost include trade and other receivables, dividends receivable and cash and cash equivalents.

#### Financial assets at fair value through profit or loss

The Cell has classified investments at fair value through profit or loss as this is the way the Cell manages and evaluates the performance of these assets.

Investments at fair value through profit or loss are recognised when the Cell becomes party to the contractual provisions of the instrument. Recognition takes place on the trade date where the purchase or sale of an investment is under a contract whose terms require delivery of the investment within the timeframe established by the market concerned.

Gains and losses arising from changes in the fair value of financial assets at fair value through profit or loss are recognised in the Statement of Comprehensive Income as they arise.

## **Notes to Financial Statements (continued)**

## 2. Summary of significant accounting policies (continued)

#### 2.5 Financial instruments (continued)

#### (a) Financial assets (continued)

Derecognition of financial assets

A financial asset is derecognised either (i) when the Cell has transferred substantially all the risks and rewards of ownership; (ii) when it has neither transferred nor retained substantially all the risks and rewards and when it no longer has control over the assets or portion of the asset; or (iii) when the contractual right to receive cash flow has expired. Any loss on derecognition is taken to other income or expenses in the Statement of Comprehensive Income as appropriate.

#### (b) Financial liabilities

The classification of financial liabilities at initial recognition depends on the purpose for which the financial liability was issued and its characteristics.

#### Financial liabilities measured at amortised cost

These consist of trade and other payables. These liabilities are initially recognised at fair value and subsequently carried at amortised cost using the effective interest method.

#### Derecognition of financial liabilities

A financial liability is derecognised when the Cell has extinguished the contractual obligations, it expires or it is cancelled. Any gain or loss on derecognition is taken to other income or expenses in the Statement of Comprehensive Income.

#### (c) Fair value estimation

The Cell classifies fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1).
- Inputs other than quoted prices included within level 1 that are more observable for the assets or liabilities, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 2).
- Inputs for the assets or liabilities that are not based on observable market data (that is, unobservable inputs) (level 3).

The level in the fair value hierarchy within which the fair value measurement is categorised in its entirety is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on observable inputs, that measurement is a level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability. The determination of what constitutes 'observable' requires significant judgement by the Cell Manager. The Cell Manager considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

The Cell invests in publicly traded equity securities and the fair values of these securities are based on the quoted market prices in an active market for identical assets without any adjustments. The fair value of the investments is based on quoted market prices at the close of trading on the reporting date. The quoted market price used for investments held by the Cell is the current bid price and these investments are included in Level 1.

## **Notes to Financial Statements (continued)**

#### 2. Summary of significant accounting policies (continued)

#### 2.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand.

#### 2.7 Share capital

The Cell has the power to issue an unlimited number of management shares of no par value and an unlimited number of participating redeemable shares of no par value.

#### (a) Management shares

The Cell has issued 2 management shares of no par value issued for £1.00 each, both of which are beneficially held by the Investment Manager. Cell management shares are not redeemable, do not carry any voting rights while participating shares are in issue, do not carry any right to a dividend, and, in a winding up rank only for a return of paid up capital.

#### (b) Participating shares

Holders of participating shares in respect of a Cell carry one vote on a show of hands and one vote (and a further part of one vote proportionate to any fraction of a share held by such holder) on a poll for each participating share held at the meetings of the Shareholders. In the event of winding up, participating shares carry a right to share in surplus assets pro rata according to their relative net asset values and then within such share classes pari passu according to the number of participating shares held. A fraction of a participating share will rank pari passu and proportionately with a whole participating share.

Participating redeemable shares are redeemable at the option of the Shareholder and are classified as financial liabilities. Shareholders may request a redemption of all or part of their participating shares of any class in the Cell on any dealing day at the net asset value per share of such class on such dealing day. The participating redeemable share is carried at the redemption amount that is payable in the Statement of Financial Position.

#### 2.8 Revenue recognition

Dividend income from financial assets is recognised in the Statement of Comprehensive Income when the Cell's right to receive payment is established. Interest income from financial assets is recognised in the Statement of Comprehensive Income on an accruals basis.

On acquisition of interest bearing investments, any accrued interest at the date of acquisition is separated from capital and is charged to the Statement of Comprehensive Income. On disposal, the Statement of Comprehensive Income is credited with the part of the proceeds attributable to accrued interest before the capital profit or loss is determined.

#### 2.9 Expenses

All expenses are accounted for on an accruals basis and are recognised in the Statement of Comprehensive Income.

#### 2.10 Taxation

The Cell has been granted exempt status under the terms of The Income Tax (Exempt Bodies) (Guernsey) Ordinance, 1989 to income tax in Guernsey. Its liability is an annual fee of £1,200 (2021: £1,200).

The Cell incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income or gains are recorded gross of withholding taxes in the Statement of Comprehensive Income. Withholding taxes are show as a separate item in the Statement of Comprehensive Income.

## **Notes to Financial Statements (continued)**

#### 2. Summary of significant accounting policies (continued)

#### 2.11 Capital risk management

The fair value of the Cell's financial assets and financial liabilities approximate to their carrying amounts at the reporting date. For the purposes of this disclosure, shares are considered to be capital.

The Cell's objectives when managing capital are to safeguard its ability to continue as a going concern in order to provide return to shareholders. There are no externally imposed capital requirements on the Cell. The Cell has no intention to borrow, other than to fund short term liquidity requirements. The Cell may arrange overdraft facility for such purposes. The Cell may pledge or otherwise grant security over its assets in connection with such borrowings. Other than borrowing to meet short term liquidity requirements, no borrowing is permitted at the Cell level.

#### 3. Significant Agreements

#### **Investment Management fee**

The Cell is managed by IP Fund Managers Guernsey Limited (the "Manager"), a management company incorporated in Guernsey, providing management services to the Cell under the terms of the management agreement in place. The investment Manager earns a fee of 0.30% of the Net Asset value of the Cell attributable to the Class of Participating Shares or \$15,000 per annum, whichever is higher.

The fees of the Administrator are payable by the Investment Manager out of the fees payable to the Investment Manager and are not charged separately.

#### **Cell Management fee**

Flagship Asset Management (Pty) Limited is the Cell Manager. The Cell Manager receives a fee per share class out of the assets of the Cell, calculated at each valuation point as a percentage of the Net Asset Value of the Cell as follows:

Class A Shares - 1.5% per annum Class B Shares - 0.0% per annum Class C Shares - 0.65% per annum

#### Performance fee

No performance fee is applicable.

#### Custodian fee

The Cell engaged the services of Butterfield Bank (Guernsey) Limited to provide custodian services and is entitled to a fee for the services rendered to the Cell of 0.05% per annum of the Net Asset Value of the Cell attributable to the Class of Participating Shares or £6,500 per annum, whichever is higher.

#### Directors' fee

Each Director of the Company is entitled to receive a single annual director's fee of up to \$10,000 per annum. This will be paid by the Cell pro rata to its Net Asset Value, or otherwise, out of the assets of the Cell, which calculation shall be at the sole discretion of the Directors.

## **Notes to Financial Statements (continued)**

## 3. Significant Agreements (continued)

#### **Distribution Partner fee**

The Cell has appointed Flagship Asset Management (Pty) Limited as the Distribution Partner to promote and market the Cell. As the Cell Manager and the Distributor are the same person, no Distributor fee shall be payable.

#### 4. Financial risk management

The Cell's activities and investment objectives expose it to a variety of financial risk: market risk (which is made up of price risk, interest rate risk and currency risk), credit risk and liquidity risk (including cash flow risk). The Cell's overall risk management programme seeks to maximise the return derived for the level of risk to which the Cell is exposed and focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Cell's financial performance. The following policies and procedures to mitigate risk have been in place throughout the year.

#### 4.1 Market risk

Market price risk is the risk that the fair value of future cash flows will fluctuate because of changes in market prices, other than those arising from currency or interest rate risk. The Cell is subject to market price risk as it trades primarily in equities and equity-based instruments. Through its investment in traded securities and instruments, the Cell is subject to market movements in the equity and bond markets.

All investments present a risk of loss of capital. The Cell Manager moderates this risk through a careful selection of securities and other financial instruments within specified limits. The maximum risk resulting from financial instruments is determined by the fair value of financial instruments. The Cell's overall market position is monitored by the Cell Manager and are reviewed by the Board of Directors.

The Cell's market price risk is managed through diversification of the investment portfolio by exposure to varying product categories, hence concentration of risk is minimised.

The following considers the Cell's sensitivity to a 10% increase or decrease in market prices, with 10% being the sensitivity rate used to report price risk internally to key management personnel and representing management's assessment of the reasonably possible change in market prices.

At 31 October 2022, if market prices had been 10% higher with all other variables held constant, the increase in the fair value of financial assets at fair value through profit or loss would have been \$1,466,061 (2021: \$2,928,591). An equivalent decrease in market prices would have resulted in an equivalent, but opposite, impact.

#### 4.2 Interest rate risk

The Cell's interest-bearing financial assets and liabilities expose it to risks associated with the effects of fluctuations in the prevailing levels of market interest rates on its financial position and cash flows.

The majority of the Cell's financial assets and liabilities are non-interest bearing. As a result, the Cell is not subject to significant amounts of risk due to fluctuations in the prevailing levels of market interest rates. Any excess cash and cash equivalents are invested at short-term market interest rates.

As this risk is not significant, no quantitative disclosures have been presented.

## **Notes to Financial Statements (continued)**

#### 4. Financial risk management (continued)

#### 4.3 Currency risk

Currency risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in foreign currency exchange rates. The Cell holds assets including investments denominated in currencies other than US Dollar, the functional currency, however this is considered as part of the price risk of the investments. There is no other material exposure to currency and so no sensitivity is prepared.

In accordance with the Cell's policy, the Cell Manager monitors the Cell's currency position on a regular basis and has the ability to enter into currency and market hedging by engaging in currency transactions in the spot and forward markets to mitigate any significant currency risk.

#### 4.4 Credit risk

Credit risk is the risk that an issuer or counterparty will be unable or unwilling to meet a commitment that it has entered into with the Cell. The investments of the Cell are determined by the Cell Manager in accordance with the criteria set out in the Cell Particulars. All transactions in securities are settled/paid upon delivery using approved brokers. The risk of default is considered minimal as the trade will fail if either party fails to meet their obligation.

The Cell's maximum credit exposure is limited to cash balances and receivables recognised at the reporting date. The Cell's maximum exposure to credit risk is estimated at approximately \$7,439,548 (2021: \$4,593,253) being the sum of receivables and the value of cash held with the custodian as at the year end.

No financial assets are either past due or impaired.

#### 4.5 Liquidity risk

Liquidity risk is the risk that the Cell will encounter difficulty in meeting obligations associated with financial liabilities. The main liquidity risk is the risk that the Cell may be unable to recover funds invested through the usual redemption process which may result in the Cell having insufficient funds to settle a transaction on the due date. Due to the nature of the Cell, the majority of investments held are in marketable securities that are readily tradable and have reported no warnings regarding their ability to process redemptions as normal. The Cell has the ability to borrow to meet short term liquidity requirements; however, to date, the Cell has not entered into such arrangements.

The table below analyses the Cell's financial liabilities into relevant maturity groupings based on the remaining period at the Statement of Financial Position date to the contractual maturity date. The amounts in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances, as the impact of discounting is not significant.

As at 31.10.2022	Less than 1 month USD	Between 1 and 12 months USD	Greater than 12 months USD	No fixed repayment USD
Other payables	66,568	-	-	
Liabilities	66,568	-	-	<u>-</u>
Net assets attributable to participating shareholders	-	-	-	22,033,590

## **Notes to Financial Statements (continued)**

## 4. Financial risk management (continued)

#### 4.5 Liquidity risk (continued)

As at 31.10.2021	Less than 1 month USD	Between 1 and 12 months USD	Greater than 12 months USD	No fixed repayment USD
Financial liabilities at fair value through profit or loss	-	66,690	-	-
Other payables	92,370	-	-	-
Liabilities	92,370	66,690	-	-
Net assets attributable to participating shareholders	-	-	-	33,786,787

#### 4.6 Capital risk management

The capital of the Cell is represented by the net assets attributable to holders of participating redeemable shares. The Cell's objective when managing capital is to safeguard the ability to continue as a going concern in order to provide returns for unitholders and to maintain a strong capital base to support the development of the investment activities of the Cell.

The Cell Manager monitors capital on the basis of the value of net assets attributable to holders of participating redeemable shares.

## 5. Critical accounting estimates and judgements

Management makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities are outlined below.

There were no judgements made in relation to the fair value of the investments as all investments are based on active quoted market prices.

#### 6. Financial assets and liabilities at fair value through profit and loss

Movement on financial assets and liabilities at fair value through profit or loss	31 October 2022 USD	31 October 2021 USD
Opening market value at start of the year/period	29,285,906	26,701,273
Purchases at cost	19,721,370	28,997,607
Sale proceeds	(23,299,775)	(36,441,068)
Net realised (losses) gains	(2,818,268)	6,804,320
Net unrealised (losses)/gains	(8,228,620)	3,223,774
Closing market value at the end of the year/period	14,660,613	29,285,906
Represented by:	31 October 2022 USD	31 October 2021 USD
Assets at fair value through profit or loss Liabilities at fair value through profit or loss	14,660,613	29,352,596 (66,690)

## **Notes to Financial Statements (continued)**

## 6. Financial assets and liabilities at fair value through profit and loss (continued)

	31 October 2022 USD	31 October 2021 USD
Net gains from financial assets and liabilities at fair value		
through profit or loss		
Net realised (losses)/gains	(2,818,268)	6,804,320
Net unrealised (losses)/gains	(8,228,620)	3,223,774
Net (losses)/gains on financial assets and liabilities held at fair value through profit and loss	(11,046,888)	10,028,094

#### Fair value measurements recognised in the Statement of Financial Position

The following tables analyse within the fair value hierarchy the financial assets and liabilities measured at fair value as at 31 October 2022 and 31 October 2021:

31 October 2022	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
Equities	8,699,203	12,710	208,643	8,920,556
Collective Investment Schemes	5,740,057	,	-	5,740,057
Options _	-	-	-	-
<u> </u>	14,439,260	12,710	208,643	14,660,613
_				_
31 October 2021	Level 1	Level 2	Level 3	Total
	USD	USD	USD	USD
Equities	20,659,915	-	180,499	20,840,414
Collective Investment Schemes	8,481,762	-	-	8,481,762
Options	(36,270)	-	-	(36,270)
_	29,105,407	·	180.499	29,285,906

**Share capital**The Cell has an authorised share capital of 100 Management shares of £1.00 each and an unlimited number of no par value participating redeemable shares.

Management Shares in Issue	31 October 2022 USD	30 June 2021 USD
Management shares (2 shares of £1.00 each)	3	3

Participating Redeemable Shares	Class A Year ended 31 October 2022		Class A Period ended 31 October 2021	
	No of shares	USD	No of shares	USD
Balance at the beginning of the year/period	23,168,134	19,728,347	27,025,142	24,229,657
Issued during the year/period	173,846	223,963	357,319	523,258
Redeemed during the year/period	(249,888)	(255,008)	(4,214,327)	(5,024,568)
Balance at the end of the year/period	23,092,092	19,697,302	23,168,134	19,728,347

## **Notes to Financial Statements (continued)**

## 7. Share capital (continued)

	Class B Year ended 31 October 2022		Class B Period ended 31 October 2021	
	No of shares	USD	No of shares	USD
Balance at the beginning of the year/period	-	-	357,062	(181,733)
Issued during the year/period	-	-	-	-
Redeemed during the year/period	-	-	(357,062)	(569,192)
Adjustment on redemption	-	(750,925)	-	750,925
Balance at the end of the year/period	-	(750,925)	-	-

Refer to note 2.7 for the rights attached to each class of share.

## 8. Net asset value per participating redeemable share

31 October 2022	NAV per share USD	Net assets attributable USD	Shares in issue
Class A	0.95	22,033,590	23,092,092
Total	_	22,033,590	23,092,092
31 October 2021	NAV per share USD	Net assets attributable USD	Shares in issue
Class A	1.46 _	33,786,787	23,168,134
Total		33,786,787	23,168,134

#### Reconciliation of Traded Net Asset Value to Reported Net Asset Value

The Cell's traded Net Asset value differs to the reported Net Asset value by the pricing of the investment securities at Bid prices in the reported Net Asset value versus Mid prices used in the traded Net Asset value. There is also a difference due to the accruals between the last day of the valuation period and the last day of the financial year end of the Cell.

	31 October 2022	31 October 2021
	USD	USD
Traded Net Asset Value	22,075,825	33,808,932
Bid price adjustments	(42,235)	(18,445)
Accruals	<del></del>	(3,700)
Reported Net Asset Value	22,033,590	33,786,787

## **Notes to Financial Statements (continued)**

#### 9. Related party transactions

A party is considered to be a related party if it has the ability to exercise control over the Cell or exercise significant influence over the Cell in making operational and financial decisions.

#### **Directors**

Simon Sharrott is a Director of IP Fund Managers Guernsey Limited (the "Investment Manager") which is the sole shareholder to IPFM Guernsey ICC Limited (the "ICC"). He is also an investment Director of Ravenscroft Optimal Portfolio Management Limited (previously MitonOptimal Portfolio Management (CI) Limited "MOPMCI")), a Guernsey registered company, which provides sub-investment management services to the Investment Manager and is a shareholder of MitonOptimal International Limited which owns 100% of MOPMCI and 28.5% of IP Fund Managers Guernsey Limited.

Brett Paton is a Director and the holder of 4.75% shares of the Investment Manager. He is also a Director of IP Management Company (RF) Pty Ltd, the representative for the distribution of the ICC's cells in South Africa.

James Tracey was a Director of the Investment Manager and JTC Fund Solutions (Guernsey) Limited, the administrator and secretary to the Investment Manager, the ICC and the ICC's cells until 29 April 2022. Graham Sleep was appointed as a Director of the Company with effect from 21 April 2022. He is also a Director of the Administrator.

During the year/period the Directors earned fees of \$1,476 (2021:1,433) of which \$2,757 (2021: 1,507) remained outstanding at year end.

#### **Investment Management Fees**

During the year/period the Investment Manager earned management fees of \$79,862 (2021: \$515,974) of which \$5,538 (2021: \$42,869) remained outstanding at year end.

#### **Cell Management Fees**

Flagship Asset Management (Pty) Limited is the Cell Manager and the holder of 100% of the Class C shares in the Investment Manager.

During the year/period the Cell Manager earned \$399,325 (2021: \$103,409) of which \$27,690 (2021: \$8,574) remained outstanding at year end.

#### 10. Ultimate controlling party

In the opinion of the Directors there is no ultimate controlling party as no one party has the ability to direct the financial and operating policies of the Cell.

#### 11. Subsequent events

There were no material events after the reporting date which require disclosure in these financial statements.